BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 7812946)

  • 1. Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations.
    Bardeesy N; Beckwith JB; Pelletier J
    Cancer Res; 1995 Jan; 55(2):215-9. PubMed ID: 7812946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor.
    Malkin D; Sexsmith E; Yeger H; Williams BR; Coppes MJ
    Cancer Res; 1994 Apr; 54(8):2077-9. PubMed ID: 8174107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations of p53 in Wilms' tumors.
    Takeuchi S; Bartram CR; Ludwig R; Royer-Pokora B; Schneider S; Imamura J; Koeffler HP
    Mod Pathol; 1995 Jun; 8(5):483-7. PubMed ID: 7675765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anaplasia and drug selection-independent overexpression of the multidrug resistance gene, MDR1, in Wilms' tumor.
    Re GG; Willingham MC; el Bahtimi R; Brownlee NA; Hazen-Martin DJ; Garvin AJ
    Mod Pathol; 1997 Feb; 10(2):129-36. PubMed ID: 9127318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restoration of p53 function in anaplastic Wilms' tumor.
    Delatte SJ; Hazen-Martin DJ; Re GG; Kelly JR; Sutphin A; Tagge EP
    J Pediatr Surg; 2001 Jan; 36(1):43-50. PubMed ID: 11150436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunophenotype, mRNA expression, and gene structure of p53 in Wilms' tumors.
    el Bahtimi R; Hazen-Martin DJ; Re GG; Willingham MC; Garvin AJ
    Mod Pathol; 1996 Mar; 9(3):238-44. PubMed ID: 8685221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome.
    Lahoti C; Thorner P; Malkin D; Yeger H
    Am J Pathol; 1996 May; 148(5):1577-89. PubMed ID: 8623926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephroblastoma (Wilms' tumor): a model system of aberrant renal development.
    Re GG; Hazen-Martin DJ; Sens DA; Garvin AJ
    Semin Diagn Pathol; 1994 May; 11(2):126-35. PubMed ID: 7809506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infrequent mutation of the WT1 gene in 77 Wilms' Tumors.
    Gessler M; König A; Arden K; Grundy P; Orkin S; Sallan S; Peters C; Ruyle S; Mandell J; Li F
    Hum Mutat; 1994; 3(3):212-22. PubMed ID: 8019557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
    Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
    Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infrequent p53 gene mutations and lack of p53 protein expression in clear cell sarcoma of the kidney: immunohistochemical study and mutation analysis of p53 in renal tumors of unfavorable prognosis.
    Hsueh C; Wang H; Gonzalez-Crussi F; Lin JN; Hung IJ; Yang CP; Jiang TH
    Mod Pathol; 2002 Jun; 15(6):606-10. PubMed ID: 12065773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
    Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
    J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
    Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M
    Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 expression in Wilms' tumor: a possible role as prognostic factor.
    Beniers AJ; Efferth T; Füzesi L; Granzen B; Mertens R; Jakse G
    Int J Oncol; 2001 Jan; 18(1):133-9. PubMed ID: 11115550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of apoptosis, cell proliferation, and drug resistance genes in pediatric Wilms' tumors.
    Ramachandran C; Melnick SJ; Escalon E; Jhabvala P; Khatib Z; Alamo A; Smith S
    Anticancer Res; 2000; 20(5C):3759-65. PubMed ID: 11268451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations.
    Bardeesy N; Falkoff D; Petruzzi MJ; Nowak N; Zabel B; Adam M; Aguiar MC; Grundy P; Shows T; Pelletier J
    Nat Genet; 1994 May; 7(1):91-7. PubMed ID: 8075648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour.
    Park S; Bernard A; Bove KE; Sens DA; Hazen-Martin DJ; Garvin AJ; Haber DA
    Nat Genet; 1993 Dec; 5(4):363-7. PubMed ID: 8298644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical expression of p53 proteins in Wilms' tumour: a possible association with the histological prognostic parameter of anaplasia.
    Cheah PL; Looi LM; Chan LL
    Histopathology; 1996 Jan; 28(1):49-54. PubMed ID: 8838120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bilateral wilms tumor with TP53-related anaplasia.
    Popov SD; Vujanic GM; Sebire NJ; Chagtai T; Williams R; Vaidya S; Pritchard-Jones K
    Pediatr Dev Pathol; 2013; 16(3):217-23. PubMed ID: 23387809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of proto-oncogene Bcl-X(S/L) expression in Wilms tumor.
    Basta-Jovanović G; Radonjic V; Stolic I; Nenadovic M; Brasanac D; Jovanovic D; Radojevic-Skodric S
    Ren Fail; 2005; 27(1):13-8. PubMed ID: 15717629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.